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Predictors of the progression of renal disease in the Modification of
Diet in Renal Disease Study. The Modification of Diet in Renal Disease
(MDRD) Study examined the effects of dietary protein restriction and
strict blood pressure control on the decline in glomerular filtration rate
(GFR) in 840 patients with diverse renal diseases. We describe a
systematic analysis to determine baseline factors that predict the decline in
GFR, or which alter the efficacy of the diet or blood pressure interven-
tions. Univariate analysis identified 18 of 41 investigated baseline factors
as significant (P < 0.05) predictors of GFR decline. In multivariate
analysis, six factors—greater urine protein excretion, diagnosis of poly-
cystic kidney disease (PKD), lower serum transferrin, higher mean arterial
pressure, black race, and lower serum HDL cholesterol—independently
predicted a faster decline in GFR. Together with the study interventions,
these six factors accounted for 34.5% and 33.9% of the variance between
patients in GFR slopes in Studies A and B, respectively, with proteinuria
and PKD playing the predominant role. The mean rate of GFR decline
was not significantly related to baseline GFR, suggesting an approximately
linear mean GFR decline as renal disease progresses. The 41 baseline
predictors were also assessed for their interactions with the diet and blood
pressure interventions. A greater benefit of the low blood pressure
intervention was found in patients with higher baseline urine protein.
None of the 41 baseline factors were shown to predict a greater or lesser
effect of dietary protein restriction.
patients in a standardized manner [6] using renal clearance of
1251-iothalamate. Data from this study provide a unique opportu-
nity to prospectively examine the changes in renal function over
time in a large group of patients with chronic renal disease of
different causes and seventies.
In this paper we present a systematic and exhaustive investiga-
tion of which baseline factors are individually predictive of
subsequent progression, and develop a minimal multivariate
model of baseline factors that are jointly predictive of progression.
This is relevant to the clinically important issue of predicting
subsequent disease progression from factors that are currently
observable, and expands on previous MDRD publications that
have related progression to subgroups based on a small number of
selected variables [7, 16, 32]. In addition, we systematically
examined our data to identify subgroups of our patients identifi-
able at entrance into the study in whom the two interventions—
dietary protein restriction and strict blood pressure control—
might have had more or less effect in preserving renal function.
Methods
Patients and interventions
Several papers on the progression of chronic renal disease have
reported that the decline in inverse serum creatinine over time is
either linear [1, 2] or possibly exponential [2]. However, little is
known about changes in renal function viewed prospectively in
patients with renal disease of different causes or degrees of
severity, and neither have the factors that might predict subse-
quent progression been extensively studied. In the Modification of
Diet in Renal Disease (MDRD) Study [3—5], 840 patients with
diverse renal diseases and with initial glomerular filtration rates
(GFRs) ranging from 13 to 55 ml/min/1.73 m2 were followed for
periods up to 3.5 years. Extensive baseline information about
patient demography, history, diet, physical examination, and
laboratory values was collected, and GFR was determined in all
The institutions and investigators who participated in the study are
listed in [5].
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The MDRD Study was a multicenter, randomized prospective
trial to determine the effectiveness of dietary protein restriction
and strict blood pressure control on the progression of renal
disease. The rate of decline in GFR was the primary outcome.
Details of the MDRD Study design [3], the baseline characteris-
tics of the patients [4], and the major outcomes of the study [5, 7,
8] have been published.
Patients were divided into two studies based on GFR at the
time of randomization. Patients with GFRs between 25 and 55
mI/min/1.73 m2 (N = 585, Study A) were randomly assigned to a
usual protein diet (protein 1.3 g/kg/day, phosphorus 16 to 20
mg/kg/day) or to a low protein diet (protein 0.58 g/kg/day,
phosphorus 5 to 10 mg/kg/day). Patients with GFRs between 13
and 24 ml/min/1.73 m2 (N = 255, Study B) were randomly
assigned to a low protein diet as in Study A or to a very low
protein diet (0.28 g/kg/day, phosphorus 4 to 9 mg/kg/day), supple-
mented with a ketoacid-amino acid mixture (0.28 g/kg/day) [5]. In
both Study A and Study B, patients were also assigned randomly,
using a factorial design, to a usual blood pressure goal [mean
arterial blood pressure (MAP) 107 mm Hg, equivalent to
140/90 mm Hg] or to a low blood pressure goal (MAP goal 92
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mm Hg, equivalent to 125/75 mm Hg). In both blood pressure
groups, the MAP goals were 5 mm Hg higher for patients who
were more than 60 years old at entry into the study.
Measurements
Protein intake was monitored by monthly 24-hour urinary urea
nitrogen determinations during baseline and follow-up [9]. Di-
etary intakes for various nutrients were also estimated from
three-day diet records at the beginning and end of baseline and
every two months during follow-up. MAP, estimated as systolic
pressure >< diastolic pressure X 2/3, was monitored monthly
during baseline and follow-up using a standardized Hawksley
random zero sphygmomanonieter (Copiague, NY, USA). Blood
and urine samples were analyzed for hematologic and biochemical
characteristics at the beginning and end of baseline. Patients were
classified into one of nine renal diagnoses on the basis of data
obtained at the second monthly baseline visit from information in
medical records and review of available historical information [4].
In the present paper, they are classified into three renal diagnostic
categories: polycystic kidney disease (PKD; N = 200); glomerular
diseases including non-insulin dependent diabetic nephropathy
and hereditary nephritis (N = 256); and other or unknown renal
diseases (N = 384).
GFR was measured as described [61 using the renal clearance of
'251-iothalamate just before random assignment, at two and four
months after assignment, and every four months thereafter. The
period of follow-up during which GFR determinations were
obtained averaged 2.3 years in Study A and 2.2 years in Study B.
In Study A, the following numbers of the initially randomized 585
patients were still in follow-up at one, two, and three years: 553,
381, and 143. In Study B, the following numbers of the initially
randomized 255 patients were still in follow-up at one, two, and
three years: 219, 137, and 62. Eleven patients had no follow-up
GFR measurements, and thus contributed only minimally to the
analyses of GFR decline. We were able to determine for all
patients the occurrence of renal failure or death by the end of the
study.
Statistical methods
Definition of covariates. We selected 41 baseline covariates for
evaluation as predictors of progression based on a priori consid-
erations. The Appendix provides a list of these covariates, as well
as details regarding the methods of constructing derived baseline
and follow-up variables.
Analyses of GFR slopes. As reported elsewhere [5], in Study A
both the low protein diet and the low blood pressure interventions
produced a small but statistically significant reduction in GFR
during the first four months after randomization. Thereafter, both
of these interventions led to a significant reduction in the steep-
ness of the GFR slope [5]. Therefore, in Study A, the change in
GFR was evaluated using two-slope models in which each patient
was assumed to have an initial GFR slope during the first four
months of follow-up, and a possibly different slope thereafter.
Based on these two-slope models, the overall mean rate of change
in GFR over three years was assessed in Study A by a time-
weighted average of the initial and final GFR slopes. For Study B,
the mean rate of decline in GFR was constant over time [5]. Thus,
the change in GFR was evaluated using a one-slope model. The
degree to which each of the 41 baseline covariates predicted GFR
slope was estimated using mixed effects models described in the
Appendix.
Univariate and multivariate analyses of predictors of GFR slope.
GFR slopes determined as above were related to the 41 selected
baseline covariates in both univariate and multivariate regression
analyses. All analyses of the effects of the baseline covariates
controlled for diet and blood pressure group assignments to
remove any biases caused by imbalances of the baseline covariates
at randomization. To identify a minimal set of baseline covariates
that were independent, significant predictors of GFR slope, we
used backward selection to simplify our multivariate models. For
consistency between Study A and Study B, we chose to create
multivariate models for these two studies containing the same
minimal set of baseline predictors. Therefore, initially both mod-
els contained each baseline factor with a significant univariate
predictive value in either Study A or Study B. Renal diagnosis was
entered as two binary covariates: polycystic kidney disease
(present or not) and glomerular disease (present or not), with
"other" being indicated by the absence of the two preceding
diagnoses. At each step of backward elimination, the surviving
factors were ordered by the smaller of their P values in Study A
and in Study B, and the factor in which this value was the largest
was dropped from both models until a pair of minimal models was
obtained in which all factors were significant (P < 0.05) in either
Study A or Study B. In Study B, we also evaluated their prediction
of time to renal failure or death.
Interactions of baseline covariates with diet and blood pressure
groups and with achieved protein intake and blood pressure. We also
searched systematically for subgroups of patients in which the
interventions differed in effectiveness. For each of the 41 variables
listed in the Appendix, for each study (A and B), and for each
randomization factor (diet or blood pressure), we constructed a
multivariate model predicting GFR slope as a function of the six
baseline predictors, the studied covariate, the randomization
group, and an interaction term of the studied covariate with the
assigned randomization group. Because of the large number of
independent tests to be performed (2 * 2 * 41),we anticipated that
several of these models would indicate a nominally significant
interaction by chance alone. As a confirmatory test, we therefore
also constructed a second set of models containing each of the
terms identified above, plus either mean follow-up protein intake
or follow-up blood pressure (as appropriate) and an interaction
term for the studied covariate and either follow-up protein intake
or blood pressure. The inclusion in this second set of models of
interaction terms of the covariate with both randomized group
and with the follow-up achieved protein intake or blood pressure
assures that the tests for these interactions are approximately
independent. A significant interaction of a baseline covariate with
one of the randomization factors (identified in the first set of
models) was considered to be reliable only if a significant inter-
action was also found with the follow-up achieved protein intake
or blood pressure in the second set of models.
Results
Relationship between baseline GFRs and follow-up GFR slopes
We first examined the impact of initial GFR on the GFR slope
during follow-up. The mean (SD) decline in GFR during follow-up
was 3.8 (4.2) mt/mm/year in patients with baseline GFRs from 25
to 55 ml/min/1.73 m2 (Study A) and 4.0 (3.1) mI/mm/year in
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Fig. 1. Follow-up GFR slopes as a function of
baseline GFR. The best linear unbiased
predictors of mean GFR slope over three years
in Study A or overall GFR slope in Study B are
shown as a function of baseline GFR. The
lower, middle, and upper lines indicate the
10th, 50th, and 90th percentiles of the
estimated GFR slopes, respectively. The slope
estimates were computed using a two-slope
mixed-effects model in Study A and an
informative censoring model in Study B. The
variability of the GFR slopes is higher at higher
levels of baseline GFR.
patients with baseline GFRs from 13 to 24 ml/min/i.73 m2 (Study
B). Figure 1 displays each patient's follow-up GFR slope estimate
as a function of baseline GFR. The median rate of decline in GFR
is essentially constant over the range of initial GFRs, with the
exception of a small trend toward a steeper median rate of decline
among patients with lower initial GFRs in the Study B range. Also
apparent is the large variability in the rates of progression from
individual to individual at all levels of initial GFR. Slopes ranged
from positive values (increases in GFR over time) to negative values
(indicating a GFR decline) as great as 10 ml/min/year. At all levels of
initial GFR there are at least some patients whose follow-up GFR
levels are stable or improving [107 of 553(19%) and 27 of 219(11%)
of patients in Studies A and B with at least one year of GFR
follow-up had least squares slopes  01. That is, renal function may
stabilize for periods as long as two to three years, despite initial
progression to GFRs as low as 15 mI/mm/I .73 m2.
There was a slightly but significantly greater variability in the
rates of change at higher initial GFRs. This variability appears to
he caused primarily by an increased fraction of patients with very
high rates of loss of GFR among patients with higher initial GFR
values. This circumstance may simply reflect the low likelihood of
identifying a patient whose GFR is initially low and whose disease
is progressing rapidly. Such patients advance to renal failure
rapidly, and few will be present in the "pre-ESRD" population at
any given time. The increased variability of GFR slopes at higher
initial GFR levels is also consistent with the higher fraction of
"non-progressors," defined as patients with zero or positive GFR
slopes, with initial GFRs in the Study A range.
Baseline characteristics predicting follow-up GFR slope
Univariate analyses. We tested each of the 41 baseline charac-
teristics possibly related to rate of progression (Appendix) sepa-
rately in Study A and Study B for their ability to predict follow-up
GFR slopes. Eighteen characteristics (Table 1) were significantly
(P < 0.05) related to follow-up GFR slope in one or both studies.
For categorical variables, such as renal diagnosis, the coefficient
(and its standard error) is the mean (SE) difference in GFR
decline between groups of patients with or without the predictor
variable (Table 1, columns 2 and 5). For example, in Study A
mean GFR decline was 3.56 (0.41) ml/min/year faster in patients
with PKD than in patients with diseases other than PKD and
glomerular disease (P < 0.001). In Study B, it was 1.59 (0.41)
mI/mm/year faster in patients with PKD than in patients with
diseases other than PKD and glomerular diseases (P < 0.001). For
continuous variables, the coefficient (and its standard error) is the
mean (SE) of the change in GFR decline for each unit change in
the predictor variable. For example, in Study A, a 1.0% increase
in urine protein excretion is associated with a faster mean GFR
decline by 1.0% of approximately 1.04 (0.12) mI/mm/year (P <
0.001). In Study B, a 1.0% increase in the urine protein excretion
is associated with a faster mean GFR decline by 1.0% of approx-
imately 0.771 (0.153) ml/min/year (P < 0.001). Interpretation of
these coefficients is facilitated by numerical examples. In Study A,
mean GFR declined 1.44 (0.16) ml/min/year faster in patients with
urine protein excretion of 1.0 g/day compared to patients with
urine protein excretion of 0.25 g/day. It declined 2.58 (0.29)
mI/mm/year faster in patients with protein excretion of 3.0 g/day
compared to patients with protein excretion of 0.25 g/day. In
Study B, mean GFR declined 1.07 (0.21) and 1.92 (0.38) ml/min/
year faster in patients with protein excretion of 1.0 and 3.0 g/day,
respectively, compared to patients with urine protein excretion of
0.25 g/day. These analyses combined patients assigned to the
different diets and blood pressure groups. As described below, the
relationship of baseline proteinuria to subsequent GFR decline
differed for patients assigned to the usual and low blood pressure
groups.
Predictive power can be ranked among characteristics with
continuous values and among those with dichotomous values by
comparing their standardized beta coefficients (Table 1, columns
3 and 6). The standardized beta coefficients represent the mean
change in GFR slope (in mI/mm/year) associated with an increase
in the baseline covariate equal to 1 SD. The sign of the coefficient
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Table 1. Baseline covariates significantly associated with GFR slope mi/mm/year
—1.59 0.413"
—1.79 0.597"
indicates the direction of the association: a minus sign indicates a
faster (more negative) GFR decline as the baseline covariate
increases, while a plus sign indicates a slower (less negative) GFR
decline as the baseline covariate increases. The magnitude of the
coefficients indicates the relative strength of the association of
GFR slope with the respective baseline covariate. The ranking of
the predictive power of these 18 baseline covariates was similar
among patients in Study A and Study B. In both studies, the
baseline characteristics with the strongest impact on rate of
progression were urine protein excretion and renal diagnosis
(glomerular disease, polycystic kidney disease, or other). The
relationships between these two characteristics and GFR slope
were examined more closely.
In Figure 2, the estimated GFR slope is plotted against baseline
urine protein excretion for each patient in Studies A and B
combined. As reported elsewhere [5, 7], patients with higher
baseline urine protein excretion had significantly slower loss of
GFR if they were assigned to the low blood pressure goal than if
they were assigned to the usual blood pressure goal; therefore the
patient's assigned blood pressure goal is also indicated in Figure
2. This Figure demonstrates that patients with greater urine
protein excretion had, as a group, only moderately higher rates of
loss of GFR than those with less urine protein excretion. How-
ever, among patients with greater urine protein excretion, those
assigned to the usual blood pressure goal contained a subset with
a rapid loss of GFR. Few patients with a similar degree of
proteinuria but assigned to the low blood pressure goal had so
rapid a loss of GFR. The median rate of loss of GFR in the groups
with low and usual blood pressure goals is similar for patients with
baseline urine protein excretion below 0.5 to 1.0 g/day, but above
these values the medians diverge, showing the slower progression
among those assigned to the low blood pressure target.
The distribution of estimated GFR slopes for each of the three
renal diagnostic categories is presented in Figure 3 (Study A) and
Figure 4 (Study B). Again, the results are presented separately for
patients assigned to the usual and to the low blood pressure goals.
In both Study A and Study B, the distribution of GFR slopes for
patients with a renal diagnosis of "other" is essentially unimodal
and similar among patients assigned to the usual or to the low
blood pressure goal, demonstrating the lack of benefit of the low
blood pressure intervention in this group which had, on average,
low rates of baseline proteinuria.
Conversely, in both Study A and Study B the distribution of
GFR slopes among patients with glomerular disease assigned to
the usual blood pressure goal is much flatter and more spread out,
encompassing patients with much more rapid progression and
others with less rapid progression. The main effect on patients
with glomerular diseases assigned to the low blood pressure goal,
particularly in Study A, appears to be a reduction in the fraction
of patients with more rapid rates of progression, with little change
in the GFR slopes of the more slowly progressing group. There is
a strong association between renal diagnosis and baseline protein-
uria. The reduction in the fraction of rapidly progressing patients
with glomerular disease among those assigned to the low blood
pressure goal probably reflects the same process as does the lower
Study A Study B
Baseline Mean SD Stand. Mean SD Stand.
covariate or % Coef. Sa Beta" or % Coef. SE Beta"
Continuous variables
Ln urine protein g/day 0.27' —1.04 0.117 —1.74" o63 —0.771 0.153 —1.09"
1/Serum creatinine dl/mg 0.56 0.15 +7.79 1.34 + 1.15" 0.31 0.09 +8.44 2.70 +0.72"
MAP mm Hg 96.3 10.7 —0.098 0.019 —1.05" 96.7 10.2 —0.068 0.022 —0.69"
Serum transferrin mg/c/I 277 43 +0.022 0.005 +0.95" 264 42 +0.017 0.005 +0.72"
Serum albumin gIdi 4.03 0.32 +2.60 0.659 +0.83" 3.99 0.36 +1.86 0.666 +0.64"
Age years 52.2 12.2 +0.062 0.017 +0.75" 50.8 12.8 +0.038 0.018 +0.47"
HDL cholesterol mg/dI 40.5 13.7 +0.050 0.015 +0.68" 39.1 15.0 +0.033 0.016 +0.49"
Apolipoprotein Al mg/c/I 133 32 +0.017 0.006 +0.53" 128 31 +0.006 0.008 +0.18
Urine creatinine mg/kg/day 18.3 3.5 —0.151 0.059 —0.53" 17.2 3.3 —0.055 0.075 —0.17
Urine sodium mEq/day 157 51 —0.008 0.004 —0.42" 137 42 —0.001 0.006 —0.03
Dichotomous variables
Prior progression 41% —1.00 0.411 —0.49" 56% —1.57 0.446 0.78"
Female gender 39% + 1.52 0.416 +0.74" 41% +0.900 0.461 +0.44
Smoker 23% —1.04 0.492 —0.44" 22% —1.63 0.536 —(1.67"
Education  13 years 66% —.310 0.429 —0.15 63% —1.37 0.469 —0.66"
Black race 9% —2.24 0.754 —0.64" 5% —2.87 1.05 —0.61"
Income $25,000 47% —0.538 0.408 —0.27 44% —0.971 0.454 —0.48"
History of hypertension 85% —1.34 0.577 —0.47" 88% —0.600 (1.724 0.19
Renal diagnosis'
Polycystic kidney disease 24% —3.56 .409" — 23% —
Glomerular disease 29% —2.60 .518" 34% —
"The standardized beta coefficients represent the mean change in GFR slope (in mI/mm/year) associated with an increase in the respective baseline
covariates equal to one standard deviation. The magnitude of the coefficients indicate the relative strength of the association.
Geometric mean
"P 0.001
"0.001 <P + 0.01
"0.01 < P + 0.05
compare patients with polycystic disease and with glomerular diseases to patients with other or unknown diagnoses.
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Fig. 2. Follow-up GFR slopes as a function of
baseline urine protein excretion. The best linear° unbiased predictors of mean GFR slope over
three years in Study A or overall GFR slope in
Study B are shown as a function of baseline
01 urine protein excretion. The lower, middle, and
I upper solid lines indicate the 10th, 50th, and
90th percentiles of the estimated GFR slopes in
the low blood pressure group (0; N = 282); the
dashed lines indicate the 10th, 50th, and 90th
01 percentiles for the usual blood pressure group
(•; N = 296). The median estimated GFR
slope is inversely related to baseline urine
protein in both blood pressure groups,
I decreasing from about —2.5 mI/mm/year at a
baseline urine protein 0.05 g/day to about —4.5
at a baseline urine protein of 0.5 g/day. At
higher values of baseline urine protein, the
median estimated GFR slope declines more
rapidly in the usual than in the low blood
pressure group.
frequency of rapidly progressing patients with greater baseline
proteinuria among those assigned to the low blood pressure goal.
Patients with polycystic kidney disease assigned to either blood
pressure goal had a relatively narrow distribution of rates of
progression. On average, their rates of progression were more
rapid than those of patients with either glomerular or other renal
diseases. As reported elsewhere [16], in Study A assignment of
patients with polycystic kidney disease to the low blood pressure
goal had no significant effect on their rates of progression. In
Study B, however, assignment of the low blood pressure goal was
actually associated with a slightly more rapid rate of progression.
Multivariate analyses. Although 18 baseline covariates were
significantly associated with GFR slope, these 18 covariates are
not necessarily independent of one another. For example, as
discussed, renal diagnostic category is strongly associated with
baseline proteinuria, with the large majority of patients with
greater urine protein excretion being classified as having glomer-
ular disease. Therefore, a multivariate analysis was undertaken to
identify a minimal set of baseline characteristics that were inde-
pendent predictors of GFR slope in either Study A or B (Table 2).
Three factors—higher urine protein excretion, presence of poly-
cystic kidney disease, and lower serum transferrin—were found to
be independent predictors of faster progression in both Studies A
and B. Three other factors—black race, higher MAP, and lower
high-density lipoprotein (HDL) cholesterol—together with the
three previous factors, were also independent predictors of pro-
gression in Study A, but not in Study B. For consistency in the
model between studies, all six factors were retained in the
multivariate models used for further analysis.
Despite its strong univariate association with GFR slope, a
diagnosis of glomerular disease did not survive the backwards
selection model. In fact, after controlling for baseline proteinuria
alone, glomerular disease was not significantly associated with
GFR slope in either Study (Study A, P = 0.09; Study B, P = 0.75).
Thus, baseline proteinuria conveyed essentially all the informa-
tion regarding GFR slope that was given by a renal diagnosis of
glomerular disease. Conversely, a diagnosis of polycystic kidney
disease contributed independent predictive value because patients
with lower urine protein excretion progressed at different rates,
depending on the presence or absence of a diagnosis of polycystic
kidney disease.
The standardized beta coefficients (Table 2, columns 4 and 8)
indicate the relative predictive power of these six covariates. They
show that in both Study A and Study B, baseline urine protein and
the presence of polycystic kidney disease were by far the strongest
predictors of the rate of progression. For example, in Study A,
controlling for other baseline characteristics, mean (sE) GFR
decline was 1.51 (0.17) and 2.71 (0.30) ml/min/year faster in
patients with urine protein excretion of 1.0 and 3.0 g/day, respec-
tively, than in patients with urine protein excretion of 0.25 glday
(P < 0.001). In Study B, mean GFR decline was 1.34 (0.22) and
2.41 (0.40) mI/mm/year faster in patients with urine protein of 1.0
or 3.0 g/day, respectively, than patients with baseline urine protein
excretion of 0.25 g!day (P < 0.001). In Study A, mean (SE) GFR
declines was 3.59 (0.12) ml/min/year faster in patients with PKD
than in patients with diagnoses other than PKD and glomerular
diseases (P < 0.001). In Study B, mean (SE) GFR decline was 1.88
(0.43) mI/mm/year faster in patients with PKD than in patients
with diagnoses other than PKD and glomerular diseases (P <
0.001).
An alternative way to understand the relative importance of
these six predictors and of the two randomization groups is to
examine the fraction of variance among GFR slopes explained as
these variables are included into a predictive model (Table 3).
The total percent of variance explained by the randomization
groups and the baseline factors is 34.5% and 33.9%, in Studies A
and B, respectively. Randomization group (assignment to diet and
blood pressure goal) accounted for only 0.3% and 1.8% of the
variance in Study A and Study B, respectively. Addition of
baseline urine protein increased the explained variance by 14.0%
and 13.2% in Study A and Study B, and subsequent addition of
the polycystic kidney disease variable increased the explained
variance by an additional 18.0% and 13.9%. Addition of the four
other significant independent predictors of progression increased
the explained variance by only 2.2% and 2.1%.
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Baseline characteristics predicting time to renal failure or death in
Study B
In Study B, 128 patients (50%) progressed to renal failure or
death, so that it is reasonable to ask which baseline characteristics
might predict these outcomes. Table 4 presents the results of a
proportional hazards analysis of the impact of the six baseline
characteristics identified by the multivariate model on the risk of
renal failure or death. Because baseline GFR will obviously also
be a predictor of the risk of renal failure (where it was not a
significant predictor of GFR slope), this variable was also added
to the model. The same baseline characteristics found to he
significant independent predictors of GFR slope, together with
baseline GFR, were significant independent predictors of time to
renal failure. Thus, these characteristics appear to be robust as the
most important predictors of disease progression.
Subgroups identified by baseline characteristics in which the effects
of the dietwy and blood pressure interventions differ
A total of eight of the 41 baseline covariates had nominally
significant interactions (with P < 0.05) with the randomized blood
pressure group in Study A. Higher levels of urine creatinine, urine
protein excretion, protein intake, serum creatinine, urine phos-
phorus, total essential amino acids, male gender and black race
were associated with greater beneficial effects of the low blood
Fig. 3. Follow-up GFR slopes as a fstnction of
renal diagnosis in Study A. Estimates of the
distribution of best linear unbiased predictors
of mean GFR slope over three years in Study A
are shown for the three major renal diagnosis
groups: PKD, glomerular, and others. The
distribution of GFR slopes was more variable
among patients with glomerular disease than
for patients with PKD or for patients with other
renal diagnoses. The fraction of rapid
progressors in the glomerular disease category
in both studies is less in the low blood pressure
group than in the usual blood pressure group.
The estimated slopes among patients with PKD
5 10 were less variable and were on average steeper
than those of patients with glomerular or other
renal diseases.
pressure goal. The interactions of three of these eight factors were
confirmed by statistically significant interactions with achieved
follow-up MAP within the Study A blood pressure groups: urine
protein excretion (P < 0.001), reciprocal of serum creatinine
concentration (P = 0.009), and black race (P < 0.001). As
discussed in the Methods section, the remaining five interactions
may be spurious in view of the large number of factors considered.
Because baseline GFR did not affect the impact of the blood
pressure intervention, we believe that the impact of baseline
reciprocal serum creatinine on the blood pressure intervention
seen in Study A may reflect a tendency for individuals with greater
muscle mass (possibly males, with higher serum creatinine for any
GFR) to benefit more from the low blood pressure goal than
those with less muscle mass. The significant effects of urine
creatinine excretion and of gender on the impact of the assigned
blood pressure target are consistent with this interpretation,
although these two baseline characteristics did not significantly
modify the impact of mean follow-up MAP.
Of the 41 baseline characteristics examined, only baseline urine
protein consistently affected the impact of the blood pressure
intervention in Study B. (Interaction of blood pressure with black
race could not be tested in Study B because only 13 patients (5%)
in Study B were black.)
Of the 41 baseline covariates, a history of hypertension was
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associated with a nominally significantly greater benefit of ran-
domization to the low protein diet in Study A, while lower
baseline MAP, lower apolipoprotein Al, higher education, lower
hemoglobin, possession of two kidneys, and a slow rate of prior
progression of serum creatinine were associated with nominally
significantly greater beneficial effects of the very low protein diet
in Study B. None of these interactions with the diet intervention
could be confirmed by corresponding interactions with achieved
follow-up protein intake. However, because the range of protein
intakes among patients assigned to any given study diet was small,
the power of the latter analysis is limited.
Discussion
It is generally believed that patients with renal insufficiency,
irrespective of the cause, continue to lose renal function over
time, progressing eventually to renal failure if they survive long
enough. Indeed, it is the apparent consistency with which patients
follow this generalization that has led to hypotheses that there
might be a common final pathogenic pathway leading to renal
failure, that renal insufficiency itself might produce maladaptive
changes in the kidneys, leading to further loss of renal function
[171. This generalization of universal progression has been chal-
lenged in two studies [18, 19] that suggest that as many as 16% to
22% ofpatients with renal insufficiency have stable renal function
Fig. 4. GFR slopes as a function of renal
diagnosis in Study B. Shown are estimates of the
distribution of best linear unbiased predictors
of overall GFR slope in Study B for the three
major renal diagnosis groups: PKD, glomerular,
and others. As in Study A, the distribution of
GFR slopes was more variable among patients
5 10 with glomerular disease than for patients with
polycystic kidney disease or for patients with
other renal diagnoses.
over periods of years. Each of these studies reviewed the courses
of about 100 patients. Progression of renal insufficiency was
assessed by sequential changes in serum creatinine, and the
criterion for lack of progression was a slope of creatinine against
time that was not significantly different from zero. In the MDRD
Study, 840 patients with renal insufficiency of varying causes and
with entrance GFRs ranging from 15 to 55 ml/minhl.73 m2 were
followed for up to 3.5 years, permitting estimation of the rates of
change of their GFRs over time. Our analysis method estimated
the underlying distribution of rates of progression in the popula-
tion, free from increased variability attributable to measurement
error and short-term fluctuations in individual rates of progres-
sion. Figure 1 shows that, overall, about 85% of the patients in the
MDRD Study continued to lose GFR over time, irrespective of
their initial GFR.
Equally apparent in Figure 1, however, is that the rate of
progression is highly variable from individual to individual, rang-
ing from the loss of 10 mI/mm of GFR per year in the patients with
the most rapid progression to no loss of GFR over time. Indeed,
consistent with the two studies cited above [18, 191, approximately
15% of patients actually had increases in GFR. Thus, at any range
of initial GFR, a small fraction of patients can have stable renal
function for as long as two to three years. This large variability in
the rate of progression of renal insufficiency has obvious clinical
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Table 2. Minimal predictive model: Association between selected variables and GFR slope (mI/mm/year)
Study A Study B
Stand. Stand. P
Selected covariates Coef. SE Betaa P value Coef. SE Betaa value
Baseline urine protein g/day' —1.09 0.12 —1.83 <0.001 —0.97 0.16 —1.37 <0.001
Polycystic kidney disease —3.5 0.43 —1.54 <0.001 —1.88 0.43 —0.81 <0.001
Baseline transferrin mg/dl +0.01 0.004 +0.48 0.008 +0.01 0.004 +0.52 0.002
Black race —1.50 0.66 —0.43 0.03 —1.38 1.29 —0.29 0.29
Baseline MAP mm Hg —0.04 0.02 —0.40 0.03 —0.03 0.02 —0.28 0.19
Baseline HDL mg/dl +0.03 0.01 +0.39 .03 +0.01 0.01 +0.16 0.35
a Standardized beta coefficients represent the mean change in GFR slope (in ml/min/y) associated with an increase in the designated baseline factor
equal to one standard deviation after controlling for the other baseline variables in the model. The magnitudes of the standardized beta coefficients
indicate the relative strengths of the association of GFR slope with the respective baseline covariates.
b Natural logarithm transformation applied to baseline urine protein.
Table 3. Cumulative variance of GFR slopes in Study A and Study B
explained by successive entry of covariates into the predictive modeP'
Baseline covariate added
Study A"
cumulative variance
explained %
Study B°
cumulative variance
explained %
Randomized group
Baseline urine protein g/dayd
0.3
14.3
1.8
15.0
Polycystic kidney disease 32.3 28.9
Baseline transferrin mg/dl 33.2 31.8
Black race 33.0 33.0
Baseline MAP mm Hg 33.6 33.7
Baseline HDL mg/dl 34.5 33.9
a Cumulative variance explained is defined as the percent reduction in
the between-patient variance component for the estimated slope over 3
years in Study A and for the overall GFR slope in Study B due to the
indicated baseline covariates. Unlike the R2 in standard multiple regres-
sion analysis, the cumulative variance explained as defined here can
decrease slightly when a new variable is added to the model.
Percent reduction in the between-patient variance component for
estimated slope over 3 years in the two-slope, mixed-effects model. The
estimated slope over 3 years for each patient i as (4/36 I3i.iaitai + (32/36)
13i,fj,,al, where 13i1,jtjal and 13i,ai are the initial and final slopes for patient i.
C Percent reduction in the between-patient variance component for the
overall GFR slope in the one-slope informative censoring model.
Natural logarithm transformation applied to baseline urine protein.
implications. Given a patient presenting initially with any degree
of renal insufficiency (but no record of past levels of renal
function), one cannot make a clinically useful prediction of how
long the patient will take to progress to renal failure.
To improve the physician's ability to project the time to ESRD,
Mitch and associates [1] proposed plotting the reciprocal of serum
creatinine over time. These authors observed in a group of
patients studied retrospectively, after they had reached ESRD,
that the change in reciprocal serum creatinine over time was
approximately linear. Walser [201 has reported that loss of GFR,
like changes in inverse creatinine, are linear over time in roughly
75% of patients. However, other relationships may describe the
loss of renal function over time as well as the linear model.
Rutherford and associates 121, for example, reported an analysis
of sequential measurements of serum creatinine, concluding that
the changes in creatinine levels were explained by an exponential
model as well as by a linear change in inverse creatinine. Before
performing the major analysis of the MDRD Study, we explored
whether the individual slopes were better modeled assuming
linear or exponential changes over time. The linear model was
slightly better than the exponential model. However, over short
periods of follow-up, the two models give similar predictions. The
results presented in Figure 1 further support the linear model. If
decline in renal function were exponential over time, one would
expect that, on average, the GFR slopes would be steeper in
patients with higher initial GFRs. In fact, there was no significant
difference in the average slope as a function of initial GFR. There
was, if anything, a slightly greater rate of loss of GFR in patients
with the lowest GFRs. At the same time, the observation that
GFR did not decline in approximately 15% of the MDRD
patients indicates that even if the mean rate of decline was
approximately linear in the full MDRD population, the decline in
individual patients may be nonlinear, with periods of GFR decline
to under 55 ml/min/1.73 m2 followed by two to three years of
stable renal function.
Given the variability we found in the individual GFR slopes, it
is important to try to identify at presentation factors that predict
which patients will progress more rapidly and which less rapidly.
Not surprisingly, our systematic search for baseline covariates that
were correlated with GFR slope revealed the same two predom-
inant factors, initial proteinuria and renal diagnosis, that were
identified as important by the less formal methods previously
reported [5]. Figures 2, 3, and 4 present the distribution of GFR
slopes at different levels of initial proteinuria and in the three
different renal diagnostic categories. Several authors [18—24] have
reported the positive correlation between level of proteinuria and
rate of progression of renal insufficiency confirmed in this study.
Given the close association of a renal diagnosis of glomerular
disease with proteinuria, it is not surprising that this diagnosis is
also associated with more rapid progression.
We previously reported an interaction of our blood pressure
intervention with initial proteinuria, with a significantly greater
beneficial effect of the low blood pressure goal in patients with
higher degrees of initial proteinuria [5, 71. The data presented in
Figures 2 and 3 suggest that the GFR slopes of patients with
higher degrees of proteinuria or with glomerular disease vary over
a particularly wide range. The major effect of the low blood
pressure goal was apparently to reduce the fraction of these
patients with the more rapid rates of progression, rather than to
reduce the rates of progression of all patients in this group.
Walser and Ward [251 examined a wider range of biochemical
measures than we did. They found that the urinary excretion of
17-hydroxycorticosteroids was the strongest predictor of rates of
loss of GFR. It would be interesting to see whether this variable
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Table 4. Cox regression of time to end-stage renal disease or death by significant baseline covariates in Study B
Standardized
Variable Coef. SE x2 P value risk ratio
Baseline GFR ml/min/1.73 m2 —0.171 0.030 33.3 <0.001 0.56
Baseline urine protein5 +0.411 0.085 23.7 0.001 1.82
Polycystic kidney disease + 0.578 0.239 5.9 0.02 1.28
Baseline transferrin mgldl —0.006 0.002 6.5 0.01 0.78
Black race +0.412 0.349 1.4 0.24 1.10
Baseline MAP mm Hg +0.011 0.010 1.3 0.25 1.12
Baseline HDL mg/dl —0.004 0.006 0.4 0.52 0.94
a The standardized risk ratio give the relative risk of end-stage renal disease or death under the Cox regression model associated with an increase in
the baseline covariate of one standard deviation.
b Natural logarithm transformation applied to baseline urine protein.
might explain the particularly wide variability in progression rates
among patients with glomerular disease.
Perhaps a bit more surprising is our observation (Figs. 3 and 4)
that patients with PKD have the most rapid average rate of
progression among the three diagnostic categories. In fact, two
other studies [19, 20] have made the same observation, although
a third study found that patients with PKD progressed more
slowly than patients with other renal diseases [18]. The wide-
spread impression that PKD progresses slowly is probably attrib-
utable to the fact that the condition can be easily identified early
in its course because of family history and early hypertension. Our
impression of polycystic kidney disease is dominated by our
experience of its long course before renal insufficiency becomes
manifest. Conversely, other forms of renal disease are often not
diagnosed until renal insufficiency has developed. The MDRD
Study experience with polycystic kidney disease is presented in
greater detail elsewhere [161.
In our systematic search for baseline covariates predicting
follow-up GFR slope, we found that 18 of 41 proposed covariates
were significantly associated with GFR slope in either Study A or
Study B (Table 1). But many of these covariates are clearly
associated with one another (such as proteinuria and diagnosis of
glomerular disease, HDL cholesterol and apolipoprotein Al,
serum albumin and serum transferrin) and so give much the same
information. To identify a minimal set of baseline covariates, we
used a backwards selection method to identify six factors (Table 2;
urine protein excretion, polycystic kidney disease, serum trans-
ferrin, black race, baseline blood pressure, and serum HDL
cholesterol) that each have simultaneous, independent, statisti-
cally significant, predictive value. In a similar multivariate analysis
of 46 patients, Walser [21, 25] identified urine protein excretion
and polycystic kidney disease, together with urinary excretion of
17-hydroxycorticosteroids, as the most predictive of rapid progres-
sion of renal disease. We emphasize that the use of multivariate
methods to select a minimal set of independent predictors of
progression is statistical only and involves no judgment as to
whether the factors that survive the selection have a direct
pathogenic relationship to progression. For example, although a
diagnosis of glomerular disease has a strong univariate correlation
with GFR slope, it is eliminated in a model that also contains
baseline proteinuria, with which it is strongly correlated. This
substitution does not imply that proteinuriaperse, rather than the
presence of glomerular disease, leads to more rapid progression,
although this is one possible interpretation. It is also possible that
proteinuria survived the selection process and diagnosis of gb-
merular disease did not because proteinuria was a continuous
variable with more levels to correlate with GFR slope than renal
diagnosis, because it was more reliably determined than the renal
diagnosis (which was often made in the absence of biopsy data), or
because of a combination of these two or other factors. Similarly,
each of the other five covariates might be important because of its
own impact on rate of progression or because of an association
with another factor that is important in determining the rate of
progression.
The above having been said, the two strongest predictors of the
rate of progression in both Study A and Study B were baseline
proteinuria and a diagnosis of polycystic kidney disease, which
together explained about 25% of the variability in GFR slopes. In
comparison, the other four selected covariates increased the
explained fraction GFR slope variance by 1% or 2%. Altogether,
our minimal model explained only 29% and 34% of the variability
in GFR slopes in Study A and Study B, respectively. Clearly other
factors unidentified by us, possibly including urinary excretion of
17-hydroxycorticosteroids [25], will prove to be important and
should be sought.
It is perhaps not surprising that higher baseline blood pressure
and black race (in Study A only) were associated with significantly
faster rates of loss of GFR. Other studies have suggested that
those factors are associated with a greater risk of renal failure
[26—32]. Higher baseline serum transferrin values, which pre-
dicted slower loss of GFR, may reflect better protein nutrition.
Consistent with this relationship is the similar univariate correla-
tion of serum albumin with progression. No other baseline
nutritional characteristic examined (Table Al of the Appendix)
significantly predicted of GFR slope. Higher HDL cholesterol was
also associated with somewhat slower average rates of loss of
GFR. This association may reflect a more favorable lipid profile,
which Samuelsson et al [33] have reported to be correlated with
slower progression. Interestingly, male gender was not indepen-
dently associated with a faster rate of progression as reported in
earlier studies [341. Univariate analysis did reveal a significant
association of male gender with faster mean GFR loss (Table 1).
However, this association did not persist after controlling for the
other factors in the multivariate model.
In Study B, 127 patients (50%) either died or progressed to
renal failure permitting assessment of whether the factors predict-
ing GFR slope also predicted these clinically important end
points. As shown in Table 4, the same factors predicting of a
higher rate of loss of GFR, together with initial GFR, also
predicted of a shorter time to renal failure or death. We believe
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that this fact corroborates the value of GFR slope, which can be
determined over a much shorter interval and with greater patient
safety, as a surrogate for clinically important end points.
In addition to baseline factors, the progression of renal disease
may also be affected by factors which change during follow-up. If
the mean follow-up levels of protein intake, MAP, and the
interaction of MAP with baseline urine protein excretion are
added to the multivariate model of baseline factors given in Table
3, the total percent of variance of GFR slopes accounted for is
increased from 34.5% to approximately 42% in Study A, and from
33.9% to approximately 40% in Study B (see 7 to 8). It should be
noted, however, that some of the association of follow-up factors
with GFR slopes may reflect the influences of changes in renal
function on the follow-up factors in addition to any effects of the
follow-up factors on renal function.
We have previously reported [5, 71 an important interaction
between baseline proteinuria and the effectiveness of the low
blood pressure target [26], and a probable interaction between
patient race and the effectiveness of the low blood pressure target
[32]. In this study we systematically examined whether there were
any other subgroups of patients defined by our 41 proposed
baseline covariates that might have particular benefit from either
of our two study interventions: dietary protein restriction or strict
blood pressure control. This process again revealed the greater
beneficial effect of the low blood pressure goal among patients
with greater proteinuria, as previously reported [5]. It also con-
firmed our previous tentative observation that blacks particularly
benefitted from the low blood pressure goal [32]. Finally, it
revealed that patients with higher serum creatinine for any level of
GFR, possibly reflecting increased muscle mass, male gender, or
both, obtained greater benefit from the low blood pressure target.
Conversely, no subgroup consistently appeared to receive a
greater benefit than others from the dietary intervention, though
for technical reasons the power in this analysis is limited.
In summary, this analysis of GFR slopes and their relation with
baseline covariates has confirmed the popular impression that
most patients with renal insufficiency lose GFR over time. But the
rates of progression are quite variable, and at every level of initial
GFR, at least some patients retain stable GFRs for periods up to
three years. The two baseline factors that most strongly predict
the rate of progression are baseline proteinuria and a diagnosis of
polycystic kidney disease.
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Appendix
A.1 Specifics of covariates
Table Al lists the 41 baseline covariates evaluated as possible
predictors of progression. For statistical analyses, baseline van-
ables were averaged over all available measurements (two mea-
surements for diet records, and for serum biochemistry variables,
with the exception of uric acid, apolipoprotein Al, apolipoprotein
A2, and total plasma essential amino acids, which were measured
only once during baseline; four measurements for the results of
the 24-hour urine collections and body mass index). Exceptions to
this rule were made for baseline blood pressure, which was
defined as the mean of the baseline MAP measurements at the
close of the first and second months of baseline and baseline renal
function variables (GFR and serum creatinine) that were based
on the final baseline measurements and were used as the "time 0"
measurements for calculation of GFR slopes over time. Baseline
urine protein was transformed logarithmically and serum creati-
nine was expressed as a reciprocal to reduce positive skewness of
these variables.
Mean follow-up protein intake was defined as the mean of all
follow-up measurements of protein intake beginning with the
second monthly follow-up visit. Mean follow-up blood pressure
was defined as the mean of all MAP measurements obtained at
non-GFR visits beginning with the third monthly follow-up visit.
MAP measurements obtained at GFR visits were excluded from
the definitions of baseline and follow-up blood pressure because
they were systematically higher than MAP at non-GFR visits [10].
A.2 Models for change in GFR
In Study A GFR was related to baseline covariates using
two-slope models in which each patient is assumed to have an
initial slope in the first four months of follow-up, and a possibly
different slope thereafter. We used mixed effects models [11] of
the form:
GFR1 = Xcs + Zp1 + e (Eq.1)
where i 1, 2 585. Here, GFR1 contains the GFR measure-
ments for the ith patient, X,cs is a fixed component describing the
mean association between the covariates and GFR, Zj31 is a
random component describing the deviation of the patient's
intercept, initial and final GFR slopes from the mean intercept
and slopes, and e1 is a vector of random residuals representing the
variation of the ith patient's GFR measurements about the
regression line indicated by Xa + Z. The residuals making up
the e are assumed to independent and normally distributed with
constant variance.
Consider now the models relating GFR to one or more baseline
covariates (Tables 2 to 3). Let T denote the number of months
after randomization at the time of a GFR measurement. For each
covariate, the fixed component Xcs contains one term relating the
covariate to mean GFR at baseline (the intercept), an interaction
term between the covariate and min(T — 4, 0) to relate the
covariate to the initial mean GFR slope prior to four months
follow-up, and a second interaction term between the covariate
and max(T — 4, 0) to relate the covariate to the final mean GFR
slope after four months. The association between the covariate
and the mean rate of change of GFR over three years was
calculated by a time-weighted average of the coefficients relating
the covariate to the initial and final slopes. Additional terms were
included to relate the randomized treatment groups to the
intercept, initial and final slopes.
Next consider the models evaluating interactions of a baseline
covariate with randomized treatment group (Tables 6 and 7, first
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Table Al. Baseline factors considered for possible relationship with follow-up GFR slope
Demographic factors
Age years
Education  13 years
Body mass index
Left ventricular hypertrophy (Study A only)
Dietary factors
Protein urine; g/kg/day
Na/K urine
Na diet; mg/kg/day
Calcium diet; mg/kg/day
Blood pressure
MAP mm Hg
Renal function
Initial GFR mI/mm/I. 73 m2
Renal diagnosis
Nutrition
Albumin g/dl
Lipids
Total cholesterol mg/dl
Apo Al mg/c/i
Miscellaneous
Hemoglobin g/dl
Gender
Income (>$25,000/year)
Creatinine (urine; mg/kg/day)
Phosphorus urine; mg/kg/day
Protein diet; g/kg/day
Na/K diet
Protein restricted diet at entry
History of hypertension
Prior progression
One kidney
Transferrin mg/di
HDL cholesterol mg/dl
Apo B mg/dl
Calcium X phosphorus mg/d12
Urine protein excretiod'
(Reciprocal) serum ereatinine dl/mg
Total essential amino acids jiiW
LDL cholesterol mg/di
Uric acid mg/c/i
four columns). For these analyses, the minimal model of six jointly
significant predictors of progression (Table 3) was augmented
with interaction terms between the baseline covariate and the four
randomized groups for the baseline GFR, the initial GFR slope,
and the final GFR slope.
To evaluate the interactions between a baseline covariate and
achieved protein intake in follow-up (Tables 6 and 7, last four
columns), we further augmented the model from the above
paragraph by adding terms assessing the interaction between the
baseline covariate and mean follow-up protein intake on baseline
GFR and the initial and final GFR slopes. By retaining the
interaction terms of the baseline covariate with randomized
treatment group in the model, these latter analyses evaluated the
average of the interactions between the baseline covariate and
follow-up protein intake within each of the four treatment groups,
and are thus approximately independent of the interactions
between the baseline covariate and randomized treatment group.
We used analogous models to evaluate interactions of baseline
covariates with achieved blood pressure.
In Study B, the cumulative incidence of renal failure or death
reached approximately 50% by three years follow-up. Conse-
quently, to avoid bias due to informative censoring [3], in Study B
we used a generalization of the mixed effects model which
incorporated the time to renal failure or death [121. This model,
which assumes a lognormal distribution for the time-to-renal
failure or death, can be expressed as:
GFR =Xa + Zf3 + e
log(D) = W fi + U1 A
S = min(D, C1)
where i = I, 2 .. ., 255. The terms of Equation 2 are similar to
those of Equation 1, except that a one-slope model is used rather
than a two-slope model. In Equation 3, D represents the time to
renal failure or death for the ith patient, W is a fixed-effects
design matrix relating the predictor variables to the mean of
log(D1), U1 is a random effects design matrix relating the predictor
variables to the deviation of log(D1) from its mean, and C1 is the
administrative censoring time for observation of D at the end of
the study. An arbitrary correlation matrix between A and 3 is
allowed in this model to control for the possible association
between GFR slope and time to renal failure or death.
We constructed the fixed effects components X.a similarly to
the models described in Study A to evaluate the effects of the
baseline covariates on the mean GFR slope. Standard errors for
these analyses were estimated using the bootstrap method with at
least 800 independent bootstrap samples [131. Due to the exten-
sive computing time required by the bootstrap method, certain
analyses in Study B patients were carried out by relating the
baseline covariates to GFR slopes of individual patients with at
least eight months of GFR follow-up using unweighted linear
regression analysis. Other analyses of GFR slopes in the MDRD
Study B have shown these two methods provide similar results.
A.3 Methods for graphically representing distributions of GFR
slopes
To avoid obscuring graphical plots of the distribution of GFR
slopes with highly variable slopes from patients with shorter
follow-up, in Study A we computed the the conditional expecta-
tion of the underlying GFR slopes given the observed GFRs
under the mixed effects model (Equation I). In Study B, we used
the conditional expectation of the underlying GFR slopes given
the observed GFRs and the observed times of renal failure or
death, under the expanded model (Equations 2 to 4). The
resulting slope estimates (sometimes called best linear unbiased
predictors, or BLUPs, for the model in Study A [11]) tend to be
"shrunken" towards the mean value indicated by the fixed effects
component (Xcs) of the model for patients with shorter follow-up.
When creating a plot relating the distribution of GFR slopes to a
particular covariate (such as baseline proteinuria in Fig. 2, and
Race (black, other)
Smoking status (yes, no)
Randomization date
Na urine; mEq/day
Phosphorus diet; mg/kg/day
Calories diet; kcal/kg/day
Diet satisfaction at entry
a Classified
as glomerular disease, polycystic kidney disease, or other.
Natural logarithm transformation applied.
(Eq. 2)
(Eq. 3)
(Eq. 4)
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renal diagnosis in Figs. 3 and 4), Xcs included terms for the mean
relationship between the covariate and the mean GFR slope. We
allowed for the possibility of different amounts of dispersion of
GFR slopes at different levels of the covariates by estimating
different variances for the random effects components of the
model for each quartile of the distribution of baseline GFR and
proteinuria in Figures 1 and 2, and for each renal diagnosis
category in Figures 3 and 4.
To relate the median and the dispersion of GFR slopes to initial
GFR, the 10th, 50th, and 90th percentile curves of the slope
estimates were calculated by the running quantiles based on an
interval width of 10 baseline GFRs with subsequent smoothing by
robust locally weighted regression [14]. A similar approach was
used to relate the distribution of GFR slopes to baseline protein-
uria. Nonparametric kernal density estimates [151 were used to
represent the distribution of GFR slopes for different renal
diagnosis classifications.
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